Impax Laboratories — Q2 2015 Earnings Presentation
22 slides from Impax Laboratories's earnings presentation, Aug 10, 2015
Slide 1: Second Quarter 2015 Results
Impax Second Quarter 2015 Results August 10, 2015
Slide 2: Cautionary Statement Regarding Forward Looking Statements
Impax Cautionary Statement Regarding Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on curren
Slide 3: Agenda
Agenda mem 42 2015 Highlights and Subsequent Events ame Update on Four Key Areas of Focus mae ©6201) Guidance ee OCA ee ©2 2015 Financial Results
Slide 4: Highlights & Update
Highlights & Update Fred Wilkinson President & Chief Executive Officer
Slide 5: Q2 2015 Highlights and Subsequent Events
Q2 2015 Highlights and Subsequent Events Q2 2015 results Revenue growth of approximately 14% Tower’ acquisition enhanced Brand and Generic portfolio Launched six generic products Strong early performance from RYTARY® Specialty Pharma (Brand) business profitable « Achieving Tower acquisition strategi
Slide 6: 1. Focusing on Quality
1. Focusing on Quality Hayward « Submitted response to Form 483 on June 1 All commitments have been completed and submitted Inspection has been officially closed No formal update on status of the closure of the Warning Letter or PAI’s on multiple products Continued dialogue with agency regarding our
Slide 7: 2. Maximizing Generic Platform
2. Maximizing Generic Platform Year to Date Potential Generic Market Update on Product Launches Launches in 2015 Products Lamotrigine ODT — FTF Azelastine Nasal Olopatadine Nasal Oxymorphone IR tablet Metaxalone 400mg IR tablet Fenofibrate 120mg tablets Cyproheptadine IR tablet Current U.S. Brand/Ge
Slide 8: 2. Maximizing Specialty Pharma Platform
2. Maximizing Specialty Pharma Platform (Coritopa ond eidopa) tended Rese Coos Over 21,000 scripts since launch 14% TRx growth prior 4 weeks + Strong product interest results in enhanced physician office access + Driving awareness and adoption > 83% of commercial Rx’s approved by payers > 76% of Med
Slide 9: 3. Optimizing R&D
3. Optimizing R&D Ss ANDA Pipeline Current U.S. Brand/Generic Market Sales - $19B Pending at FDA - $98 27% Confirmed/Potential Under Development - $108 45% Potential FTF or FTM FTF or FTM 25 10 10 F a Bo Internal External Internal External [Other SOD MControled-Release SOD [ll Alternative Dosage For
Slide 10: 4. Business Development Acceleration
4. Business Development Acceleration Announced divestiture of Daraprim® for $55 million in cash » Non-core asset acquired as part of Tower acquisition » Returns approximately 8% of $700 million acquisition price Integration of Tower acquisition essentially complete » Focusing on achieving strategic
Slide 11: Financial Review
Financial Review Bryan Reasons Senior Vice President & Chief Financial Officer
Slide 12: Q2 2015 Financial Summary
Q2 2015 Financial Summary Total Net Revenues $214.2 $143.1 49.7% $188.1 13.9% Adjusted Gross Profit $1071 $678 58.0% $1212 (11.7%) Adjusted Gross Margin 50.0% 47.4% — 2.6ppts 64.4% (14.4ppts) Adjusted Research & Development Expense $17.0 $150 13.3% $21.3 (20.0%) Adjusted Selling, General & Administr
Slide 13: Q2 2015 Generic and Specialty Pharma Summary
Q2 2015 Generic and Specialty Pharma Summary GENERIC DIVISION Total Net Revenues $1747 $1287 35.7% $176.4 (1.0%) Adjusted Gross Profit $752 $579 29.9% $117.2 (35.8%) Adjusted Gross Margin 431% 45.0% — (1.9ppts) 66.5% (23.4ppts) Adjusted Operating Income $537 $420 27.9% $100.1 (46.4%) SPECIALTY PHARM
Slide 14: Improved Capital Structure
Improved Capital Structure Term Loan Termination Benefits Prior Credit Facility + $435 secured term loan + 4.5% + 1% LIBOR floor + Minimum annual interest of approximately $24 million + Restrictive covenants * $600 million unsecured convertible * 2% coupon + Adjusted annual interest of $12 million N
Slide 15: Full-year 2015 Financial Guidance Update
Full-year 2015 Financial Guidance Update $ millions | Prior Updated Adjusted Gross Margin* Mid 50% range Low 50% range Adjusted Research & Development Expense* $80 to $85 $75 to $80 Adjusted Selling, General & Administrative Expense $170 to $180 $170 to $180 Adjusted Interest Expense** Not provided
Slide 16: Key Priorities
Key Priorities
Slide 17: Q&A
Slide 18: Appendix
Appendix
Slide 19: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles reported net (loss) income to adjusted net income (Unaudited, amounts in thousands, except per share and per share data) June 30, 2015 Net (oss) income S$ (4852) Adjusted to add (deduct): Amortization ® 162 Hayward facility remediation
Slide 20: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles total Company reported cost of revenues, research and development expenses, and selling, general and administrative expenses to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development e
Slide 21: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles reported net (loss) income to adjusted EBITDA. The following table reconciles reported interest expense to adjusted (Unaudited, amounts in thousands) interest expense (Unaudited, amounts in thousands) Three months ended Three months end
Slide 22: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following tables reconcile the Impax Generics and Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) Generic Divisi